For the Quarter Ending December 2025
APAC
• In China, the Diphenhydramine Hydrochloride Price Index fell by 5.37% quarter-over-quarter, reflecting regulatory retrofits reducing throughput.
• The average Diphenhydramine Hydrochloride price for the quarter was approximately USD 15250.00/MT amid steady restocking.
• Near-term Diphenhydramine Hydrochloride Spot Price momentum strengthened as export inquiries exceeded FOB slots in December.
• The Diphenhydramine Hydrochloride Price Forecast indicates volatility with seasonal restocking and regulatory compliance influencing offers.
• Rising environmental levies and solvent-recovery retrofits pushed the Diphenhydramine Hydrochloride Production Cost Trend, tightening margins.
• Global Diphenhydramine Hydrochloride Demand Outlook remains steady due to winter respiratory season and export replenishment.
• Inventory draws and prioritized export allocations lifted the Diphenhydramine Hydrochloride Price Index modestly during December.
• Operational pauses at two FDA-audited plants reduced throughput, influencing market tightness and buyer negotiation dynamics.
Why did the price of Diphenhydramine Hydrochloride change in December 2025 in APAC?
• Regulatory-driven retrofits at FDA-audited plants reduced available capacity, tightening supply and supporting modest price increases.
• Higher environmental levies nudged conversion costs upward, shifting the Production Cost Trend and pricing behavior.
• Robust year-end export inquiries combined with seasonal pharmaceutical restocking tightened markets despite smooth port logistics.
Europe
• In Europe, the Diphenhydramine Hydrochloride Price Index declined moderately on a quarter-over-quarter basis, reflecting adequate import availability and cautious procurement.
• The average Diphenhydramine Hydrochloride price for the quarter was estimated at approximately USD 15,600.00/MT, based on CFR assessments across major pharmaceutical hubs.
• Diphenhydramine Hydrochloride Spot Price sentiment improved toward December as buyers secured incremental volumes ahead of winter demand.
• The Diphenhydramine Hydrochloride Price Forecast pointed to heightened volatility, with regulatory-driven supply discipline and seasonal restocking influencing short-term offers.
• Diphenhydramine Hydrochloride Production Cost Trend reflected upward pressure from compliance costs and energy-intensive solvent recovery processes.
• Diphenhydramine Hydrochloride Demand Outlook remained stable, supported by cold and allergy season demand from pharmaceutical formulators.
• Gradual inventory drawdowns at distributor warehouses supported firmer Diphenhydramine Hydrochloride Price Index readings during December.
• Import reliance and selective supplier approvals constrained immediate availability, limiting buyer leverage despite otherwise balanced supply.
Why did the price of Diphenhydramine Hydrochloride change in December 2025 in Europe?
• Regulatory compliance costs passed through by suppliers reduced price flexibility on spot volumes.
• Seasonal pharmaceutical demand increased restocking urgency, tightening short-term availability.
• Controlled distributor inventories and limited alternate sourcing options supported firmer pricing despite steady import flows.
North America
• In North America, the Diphenhydramine Hydrochloride Price Index softened quarter-over-quarter, reflecting earlier inventory accumulation and measured downstream procurement.
• The average Diphenhydramine Hydrochloride price for the quarter was approximately USD 15,850.00/MT, based on CFR U.S. market assessments.
• Diphenhydramine Hydrochloride Spot Price conditions firmed modestly in December as buyers covered requirements for winter pharmaceutical demand.
• The Diphenhydramine Hydrochloride Price Forecast suggested continued volatility, shaped by regulatory-linked supply constraints and inventory normalization.
• Diphenhydramine Hydrochloride Production Cost Trend showed upward bias due to environmental compliance and stable-to-higher processing expenses.
• Diphenhydramine Hydrochloride Demand Outlook stayed steady, supported by sustained OTC and prescription drug consumption during the respiratory season.
• Inventory levels at distributors gradually declined through December, lending support to Diphenhydramine Hydrochloride Price Index stabilization.
• Dependence on FDA-approved overseas suppliers limited sourcing flexibility, tightening negotiation dynamics when spot demand rose.
Why did the price of Diphenhydramine Hydrochloride change in December 2025 in North America?
• Reduced export availability from compliant plants tightened supply options for importers.
• Seasonal pharmaceutical restocking increased near-term demand, lifting spot buying interest.
• Higher compliance-linked conversion costs constrained supplier discounting, supporting modest price firming despite adequate inventories.
For the Quarter Ending September 2025
North America
• In the United States and Canada, the Diphenhydramine Hydrochloride Price Index rose by ~16.5% quarter-over-quarter, driven by distributor restocking and programmatic pharmaceutical procurement.
• The average Diphenhydramine Hydrochloride price for the quarter was approximately USD 22,533.33/MT for CFR East Coast North America imports (based on exporter reports and regional premia).
• Diphenhydramine Hydrochloride Spot Price remained firm as low inventories and steady offtake from prescription and OTC formulations supported near-term demand.
• Diphenhydramine Hydrochloride Price Forecast indicates possible mild correction into Q4 as restocking completes, but demand for allergy/cold season formulations may sustain elevated levels.
• Diphenhydramine Hydrochloride Production Cost Trend showed limited upward pressure; feedstock and energy costs were generally stable across origins.
• Diphenhydramine Hydrochloride Demand Outlook is robust for seasonal allergy and cough products, supporting continued import enquiries and distributor purchases.
• The Price Index rise reflected steady origin shipments, efficient port operations (East Coast), and aggressive sourcing to replenish tight North American stocks.
• Tight distributor inventories and prioritized pharmaceutical offtake restricted spot availability, contributing to firm offers this quarter.
Why did the price of Diphenhydramine Hydrochloride change in September 2025 in North America?
• Rapid replenishment and low on-hand stocks increased buyer competition, tightening spot supplies and driving price increases.
• Seasonal demand for allergy and cough formulations raised procurement urgency among wholesalers and formulators.
• Stable production and logistics limited cost pressures, so the price rise was primarily demand-led.
APAC
• In China, the Diphenhydramine Hydrochloride Price Index rose by 17.56% quarter-over-quarter, driven by replenishment activity.
• The average Diphenhydramine Hydrochloride price for the quarter was approximately USD 22533.33/MT reported by exporters.
• Diphenhydramine Hydrochloride Spot Price remained firm due to low inventories and pharmaceutical offtake for formulations.
• Diphenhydramine Hydrochloride Price Forecast signals modest correction as importers balance replenishment with seasonal demand normalization.
• Diphenhydramine Hydrochloride Production Cost Trend showed limited upward pressure, feedstock and energy costs remaining stable.
• Diphenhydramine Hydrochloride Demand Outlook remains strong for allergy and cough formulations, supporting export inquiry levels.
• The Price Index movement reflected stable Chinese production, smooth Shanghai port operations, and international procurement.
• Tight distributor inventories and active export demand prompted competitive sourcing, tightening spot availability this quarter.
Why did the price of Diphenhydramine Hydrochloride change in September 2025 in APAC?
• Elevated export inquiries and domestic replenishment rapidly depleted inventories, creating short-term supply tightness in September.
• Stable production and efficient Shanghai port operations prevented logistical delays, limiting upward cost pressures regionally.
• Seasonal formulation demand and advance buying by importers amplified procurement urgency, strengthening quarter Price Index.
Europe
• In Germany and major EU import hubs, the Diphenhydramine Hydrochloride Price Index rose by ~15.8% quarter-over-quarter, reflecting active replenishment and tight distributor stocks.
• The average Diphenhydramine Hydrochloride price for the quarter was approximately USD 22,900/MT for CFR Rotterdam imports (conservative regional estimate).
• Diphenhydramine Hydrochloride Spot Price firmed as European formulators replenished low inventories and competed for available cargoes.
• Diphenhydramine Hydrochloride Price Forecast signals mild correction into Q4 as purchasers balance urgent restocking with seasonal demand normalization.
• Diphenhydramine Hydrochloride Production Cost Trend remained contained; precursor availability and stable energy costs limited cost-push.
• Diphenhydramine Hydrochloride Demand Outlook stays strong for allergy and cough formulations through autumn, supporting sustained import enquiries.
• Price Index strength reflected steady Chinese exports, reliable Rotterdam logistics, and disciplined distributor tendering across the region.
• Tight warehouse stocks and active procurement narrowed spot availability, prompting competitive offers and supporting the quarterly upswing.
Why did the price of Diphenhydramine Hydrochloride change in September 2025 in Europe?
• Low distributor inventories and active replenishment by formulators increased buying urgency, tightening spot availability and lifting prices.
• Strong allergy/cough season demand and elevated export inquiries from Asia amplified procurement competition.
• Stable logistics and contained production costs meant upward moves were demand-driven rather than cost-driven.
For the Quarter Ending June 2025
North America
• Diphenhydramine Hydrochloride Spot Price reflected a steady upward movement in Q2, tracking a rising Price Index as import offers from Asia strengthened month-over-month amid global tightness.
• Diphenhydramine Hydrochloride Production Cost Trend was influenced by pass-through costs from rising bromine feedstock rates in origin markets. While local producers have maintained cost buffers, imported inputs saw cost push inflation.
• Diphenhydramine Hydrochloride Demand Outlook remained firm throughout the quarter, with sustained consumption across OTC allergy and cold-relief formulations during late spring and early summer.
• Downstream manufacturers faced narrowing sourcing flexibility due to tight global supply, prompting moderate forward bookings in May and June to secure Q3 production schedules.
• Inventories among key U.S. distributors showed gradual depletion, particularly in May, aligning with increased formulation activity and peak consumer demand.
• No major logistical bottlenecks were reported; however, lead times for Asian-origin material lengthened marginally in late Q2 due to elevated regional shipping congestion.
• Spot contract acceptance improved in June, with buyers more willing to secure bulk positions at elevated levels, citing continued upward Diphenhydramine Hydrochloride Price Forecast.
• Suppliers adjusted price bands upward in response to increased international FOB benchmarks and tightening availability in Asia, aligning local market prices with global levels.
• Price Index likely to rise further due to lagging replenishment cycles, steady OTC drug manufacturing, and limited buffer inventories; a modest increase is projected.
Asia-Pacific (China-Centric Market)
• Diphenhydramine Hydrochloride Spot Price rose sharply during Q2 2025. They increased and was assessed at USD 2,830/MT in early April to around USD 3,640/MT by end-June and marked a ~28% gain. This sharp uptrend was supported by strong domestic demand and persistent cost-driven pricing adjustments enforced by major Chinese producers.
• Diphenhydramine Hydrochloride Production Cost Trend surged due to elevated bromine feedstock costs which reduced the producer flexibility and pushed export offers upward through May and June.
• Diphenhydramine Hydrochloride Demand Outlook remained highly bullish that was driven by allergy-related formulation spikes in domestic and global markets. Formulators in Southeast Asia, India and Latin America accelerated buying.
• Manufacturers adopted controlled inventory strategies, withholding excess supply from spot markets to maintain premium pricing amidst heightened overseas interest.
• Inventory positions across major warehouses in Shanghai and Nanjing were lean by mid-June, reinforcing tightness in export availability.
• Despite monsoon-related risks, export operations proceeded smoothly with efficient port handling and no policy disruption, ensuring dependable clearance cycles.
• Spot export volumes were prioritized toward contract-bound high-margin destinations, leaving fewer allocations for open-market negotiations.
• Market participants reported contract renegotiations at higher bands due to sudden offtake surges and restocking delays among international buyers.
• Price Index is forecasted to increase modestly by 3–5%, as continued export inquiries, lean inventories, and steady domestic consumption maintain upward pressure.
Europe
• Diphenhydramine Hydrochloride Spot Price in Europe gradually escalated through Q2, with the Price Index influenced by imported cost pressure and reduced availability from Asia.
• Diphenhydramine Hydrochloride Production Cost Trend remained flat within the EU; however, rising cost push from bromine-based imports and transportation surcharges inflated end prices.
• Diphenhydramine Hydrochloride Demand Outlook strengthened in Germany, France, and the UK as seasonal allergy incidence rose and OTC sales gained traction post-April.
• Buyers faced challenges securing competitive bids in May–June, as Asian exporters prioritized domestic and high-premium markets, creating allocation stress across central EU distribution networks.
• Inventory drawdowns were noted across Belgian and Polish distribution hubs, with major generics formulators initiating early Q3 procurement to mitigate Q4 volatility risks.
• June witnessed an uptrend in buyer urgency; distributors began pre-booking July cargoes despite moderate premiums.
• Spot availability constraints, coupled with stable freight but volatile offer prices, contributed to a defensive buying strategy across several mid-tier buyers.
• Market sources indicated forward contract volumes for Q3 were secured at a ~5–7% premium compared to April, confirming upward Diphenhydramine Hydrochloride Price Forecast momentum.
• Price Index is expected to continue trending upward due to tight supply chains, sustained pharma demand, and minimal price relief on key input chemicals.
For the Quarter Ending March 2025
North America
In North America, Diphenhydramine Hydrochloride prices showed a mild downward movement through the first quarter of 2025. The market remained steady with no major price shocks. Procurement by pharmaceutical buyers stayed moderate. Many procurement teams avoided building excess stock as their current inventories were sufficient. This led to lower order volumes from some key buyers.
There was no major disruption in supply and logistics operations continued without delay. Freight and handling costs remained within normal range. The overall sentiment in the market was cautious. Suppliers did not raise prices and buyers also avoided aggressive negotiations.
Demand from downstream sectors such as allergy and cold medications was present, but not very strong. Restocking activity was limited as most players expected availability to remain stable in the short term. The small decline in price was more a result of controlled demand and well-planned inventories rather than any large supply-side factor. The market tone was soft and there was no sign of volatility or tightness.
Asia Pacific
In Asia Pacific, Diphenhydramine Hydrochloride average prices declined slightly by around 0.67 percent during the first quarter of 2025. Demand from pharmaceutical and personal care sectors was steady but not aggressive. Buyers remained cautious and avoided overstocking. Procurement was done in a planned and phased manner.
There were no signs of panic buying or urgent replenishment. Inventory levels across key buyers remained comfortable throughout the quarter. The market was also affected by a slowdown in export activity from China during the Lunar New Year period. As China is a key producer of this product, any disruption there tends to influence the whole region. However, supply was not tight.
Most exporters managed to meet scheduled deliveries without much delay. Overall logistics in the region remained smooth. There was no cost pressure from transportation or raw materials during this period. The market tone stayed soft but not unstable. Slight price corrections happened more due to subdued trading activity than any major changes in demand or production. The overall market remained calm and balanced during the quarter.
Europe
In Europe, Diphenhydramine Hydrochloride prices remained largely steady during the first quarter of 2025, with a slight downward bias. The market did not witness any strong pull from the demand side. Buyers in pharmaceuticals and personal care segments purchased only as per need. Most of them had adequate inventory from the previous quarter. There was no urgency to place large orders. Suppliers across the region were able to meet demand smoothly. There were no signs of production cuts or capacity issues. The logistics situation also stayed stable, with no major delays or backlogs.
European buyers followed a conservative approach while planning their procurement. Market participants were not expecting any sudden shift in prices or availability which also contributed to the subdued buying behaviour. The small price dip seemed more influenced by controlled purchasing activity than any structural imbalance. No significant external factors such as policy changes or trade restrictions affected the market. Overall, the quarter moved in a quiet and balanced manner with both buyers and sellers showing steady participation and price levels adjusting softly.
